Difference in mortality risk predicted by leukocyte and lymphocyte levels in COVID-19 patients infected with the Wild-type, Delta, and Omicron strains

Hongjun Zhang,Yanjun Zhao,Wenjie Li,Yaqin Chai,Xing Gu
DOI: https://doi.org/10.1097/md.0000000000037516
IF: 1.6
2024-03-09
Medicine
Abstract:Since the onset of the wild-type strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, which causes coronavirus disease 2019 (COVID-19), there have been several globally circulating multiple new variants of concern (VOC). To date, there have been 5 main lineages that are identified as the VOC by the World Health Organization, such as B.1.1.7 (Alpha), [ 1 ] B.1.351 (Beta), [ 2 ] P.1 (Gamma), [ 3 ] B.1.617.2 (Delta), [ 4 ] and B..1.1.529 (Omicron). [ 5 ] The variants are associated with increased transmissibility. [ 6 ] The Delta first reported in India in December 2020 and was fast becoming the dominant strain in many countries and regions. [ 7 ] And the Omicron variant of SARS-CoV-2 was first identified in South Africa and Botswana and was reported to the World Health Organization on November 24, 2021, as a novel variant. [ 8 , 9 ] Owing to its enhanced transmissibility, Omicron has rapidly replaced Delta as the dominant variant on a global scale. [ 10 ]
medicine, general & internal
What problem does this paper attempt to address?